Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus FLURANDRENOLIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus FLURANDRENOLIDE.
DERMA-SMOOTHE/FS vs FLURANDRENOLIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Apply 0.025% to 0.05% cream or ointment topically to affected area twice daily.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Clinical Note
moderateFlurandrenolide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gatifloxacin."
Clinical Note
moderateFlurandrenolide + Rosoxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rosoxacin."
Clinical Note
moderateFlurandrenolide + Levofloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life approximately 18–36 hours; clinical context: prolonged with hepatic impairment; supports once-daily or twice-daily topical dosing.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Renal (<1% unchanged), biliary/fecal (major route, as metabolites); <1% excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
Flurandrenolide + Trovafloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Trovafloxacin."